Synergene Therapeutics, Inc.
Clinical trials sponsored by Synergene Therapeutics, Inc., explained in plain language.
-
New hope for kids with stubborn cancers? SGT-53 trial begins
Disease control TerminatedThis early-stage study tests a drug called SGT-53 in children and young adults (ages 1-21) with solid tumors that have come back or not responded to treatment. The goal is to find the safest dose and understand side effects when given alone or with standard chemotherapy. The stud…
Phase: PHASE1 • Sponsor: SynerGene Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 08:35 UTC
-
Promising brain tumor study for kids pulled before it began
Disease control TerminatedThis study was designed for children whose brain or central nervous system (CNS) tumors had come back or were not responding to treatment. The goal was to see if adding the experimental drug SGT-53 to standard radiation and chemotherapy was safe and could shrink tumors. However, …
Phase: EARLY_PHASE1 • Sponsor: SynerGene Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC